Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis

Measurement of disease activity in systemic autoimmune disorders is often unreliable, and immunosuppressive therapy is often titrated to crude clinical response and/or onset of complications. Systemic sclerosis (SSc) presents a distinct clinical phenotype associated with specific autoantibodies. Anti-topoisomerase-1 (SCL-70) is selectively detected in 30-60% of subjects with diffuse skin and interstitial lung involvement. Such patients offer an ideal clinical model to characterize and quantify the autoantigen-specific T-cell response and its correlation with disease phenotype and activity. Human leukocyte antigen A2 (HLA-A2)-restricted topo-1 peptides were selected based on an epitope prediction algorithm. For initial studies, the best binder toPO-1(262-270) KMLDHEYTT (#262) was used alone or loaded onto an artificial antigen-presenting platform generated by coupling a dimeric major histocompatibility complex-immunoglobulin G fusion protein (RLA-A2-1g) and anti-CD28 antibodies onto magnetic beads (artificial antigen-presenting cells). Blood samples (100 ILL) from HLA-A2(+) SSc patients and cytomegalovirus (CMV) seropositive healthy control subjects were tested in an intracellular cytokine staining assay. Gamma interferon production by CD8(+) T cells was measured after stimulation with peptide #262, CMVpp65, or MART-I (irrelevant peptide). In two of five SCL-70(+) patients, peptide #262-loaded aAPCs induced a specific CD8(+) T-cell response (0.45% 0.23% of total CD8(+) cells). This response was not observed in the seven SCL-70(-) (five SSc and two CMV+) control subjects studied (0.03% +/- 0.02%). Interestingly, bronchoalveolar lavage fluid obtained from one topo-1-responsive SSc patient who had worsening respiratory function and active alveolitis showed striking enrichment of topo-I-specific CD8(+) T cells (3.94%). This small-volume ex vivo assay may prove to be a sensitive and specific tool to assess disease activity and to monitor response to therapy in patients with scleroderma.